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Rather than being homogenous, it is becoming increasingly 
clear that central nervous system (CNS) neuroinflammatory 
diseases have a broad range of immunological aetiologies. In 
particular, the discovery of novel CNS antibodies has helped 
define new clinical disease entities. A greater understanding 
of the clinical phenomenology associated with these dis-
orders will now be important to aid diagnosis and guide 
appropriate management.
Disease caused by one of these novel antibodies—
directed towards myelin oligodendrocyte glycoprotein 
(MOG), has become a more intense focus of research as 
diagnostic assays have become more reliable and specific. 
MOG is expressed within the CNS on the surface of oligo-
dendrocytes and myelin and associated with a range of adult 
and paediatric demyelinating disorders. Although acute dis-
seminated encephalomyelitis (ADEM), optic neuritis (ON) 
and transverse myelitis (TM) are all phenotypes known to 
be related to MOG antibody (MOG-Ab) seropositivity, it is 
clear that further clinical characterisation and understanding 
of treatment outcomes is needed. It may be of particular rel-
evance to distinguish these diseases from multiple sclerosis 
since standard disease modifying therapy may be ineffec-
tive and cause increased morbidity. Outcomes and treatment 
may also differ from aquaporin-4 antibody (AQP4) positive 
disease.
The three papers in this month’s journal club describe 
large cohorts of adults and children with MOG-Ab associ-
ated demyelinating disease. All aim to further characterise 
the clinical and radiological features of this disease along-
side treatment outcomes. This represents an important step 
before establishing larger, systematic, prospective studies in 
addition to clinical trials of potential therapeutic regimens.
Clinical spectrum and prognostic value 
of CNS MOG autoimmunity in adults: 
the MOGADOR study
This paper aimed to describe the clinical features and prog-
noses of patients with MOG-Ab associated disease after 
a first acute demyelinating event in a large French adult 
cohort. The clinical utility of MOG-Ab longitudinal analy-
sis was also evaluated.
Patients aged ≥ 18 years presenting with at least one clini-
cal demyelinating episode, and MOG-Ab seropositivity were 
retrospectively recruited. Demographic data were collected 
alongside clinical measures including Disability Status Scale 
(DSS), visual acuity (VA) and relapse history. In addition, 
medication use, biological aspects of disease and radiologi-
cal findings were attained where available. Comparative 
data were obtained for an AQP4 positive cohort from a pre-
existing database.
One hundred and ninety-seven patients were identified 
(M:F 1:1, 92.9% Caucasian) with a median age at presenta-
tion of 36.5 years. The most frequent phenotypes at disease 
onset were ON (60.9%) or myelitis (22.3%) either alone or in 
combination (7.6%). Other presentations included brainstem 
syndromes and encephalopathy with less frequent accom-
panying symptoms including neuropathic pain, fever, area 
postrema symptoms and seizures. Cerebrospinal fluid (CSF) 
pleocytosis was observed in 44.2% of patients, most fre-
quently present in those presenting with myelitis. CSF oli-
goclonal bands (OCBs) were only seen in a minority (5.7%). 
After a median follow-up of 15.8 months, 42.1% patients 
relapsed. The cumulative risk to reach a relapse after 2 and 
5 years was 44.8 and 61.8%, respectively, for patients with 
ON or myelitis at onset. At last follow-up, 24.7 and 10.4% 
patients presenting with non-ON phenotypes reached a DSS 
score of 3.0 and 6.0, respectively. Of patients presenting 
with ON, only 8.1% reached VA of 20/100 at the last follow-
up. In comparison to the AQP4 cohort, MOG-Ab patients 
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had a lower risk to reach a first relapse and of attaining a 
DSS score of 3 or visual acuity 20/100.
MOG-Ab patients had distinctive pontine and thalamic 
lesions on MRI imaging with cortical involvement and lep-
tomeningeal enhancement also seen. Myelitis lesions (either 
alone or with ON) at onset were longitudinally extensive in 
84.4 and 55.6%, respectively. MOG-Ab titres were higher in 
relapse compared with remission and in those with mono-
phasic disease only 2 (18.2%) became seronegative.
Comment This study adds to knowledge regarding the 
spectrum of clinical phenotypes in adult patients with MOG-
Ab positive disease. In particular, MOG-Ab patients have 
a milder disease course when compared with AQP4 posi-
tive patients. Interestingly, specific findings on MRI were 
observed in patients with MOG-associated disease, which 
may help identify these patients at an earlier stage. The 
authors acknowledge that as not all patients were diagnosed 
at onset of disease, differing treatment and managements 
may have potentially affected the disease course. In addition, 
the timing of MRI and serum samples were not standardised.
C o b o - C a l v o  A  e t   a l .  N e u r o l o g y . 
2018;90(21):e1858–e1869
Clinical course, therapeutic responses 
and outcomes in relapsing MOG 
antibody‑associated demyelination
This paper aimed to characterise the clinical course, treat-
ment and outcomes in both adult and paediatric MOG-Ab 
positive patients with relapsing disease. Fifty-nine (40 
female, 73% Caucasian) patients with relapsing demyeli-
nation were identified from 25 Australasian centres (adult 
> 16 years, n = 26; paediatric ≤ 16, n = 33). Data were ret-
rospectively collected for annualised relapse rates (ARR) 
pre- and post-treatment, therapeutic responses and Expanded 
Disability Status Scale (EDSS) outcomes.
The median age of onset for the total cohort was 12 years 
(adults 37 years, paediatrics 6) with an infectious prodrome 
present in 47%. Mean EDSS at initial presentation was 5.1 
(adults 4.4, paediatric 5.6). In total, 218 demyelinating 
episodes were identified during an average follow-up of 
61 months. Two demyelinating episodes were observed in 
33.9% patients and 66.1% patients had ≥ 3.
ADEM was the most common initial presentation in chil-
dren (36%) followed by bilateral ON (BON, 24%) and unilat-
eral ON (UON, 15%). Adults presented primarily (73%) with 
ON (BON 42%, UON 31%). TM was said to be less com-
mon. Similarly, across all relapsing episodes, ON was most 
common; UON (35%), BON (19%). ADEM was common 
in children (15%) but rare in adults (2%). TM was less com-
mon in the whole cohort (11%) but more prevalent in adults. 
Relapsing ON was the main relapsing clinical syndrome in 
the total cohort (29%) followed by neuromyelitis spectrum 
disorder (NMOSD, 25%).
A CSF mononuclear pleocytosis and elevated protein was 
observed in 58 and 37% patients respectively. OCBs were 
positive in 11%. No brain lesions were observed in 48% of 
MRI scans. With respect to treatment, all immunosuppres-
sant treatments used were associated with a reduction in 
ARR with maintenance prednisone having the lowest treat-
ment failure rate. Residual disability was observed in 58%, 
which was more likely in those with myelitis. The mean 
EDSS at latest follow-up for the total cohort was 1.3.
Comment This study increases knowledge about the clin-
ical phenotype and outcomes in both adults and children 
with MOG-Ab associated disease. The positive response to 
immunosuppressive treatment is encouraging as is the find-
ing that the majority of patients have a positive outcome. 
Limitations of the study include its retrospective design and 
the limited numbers of patients in some treatment groups. In 
addition, some patients were on several therapeutic agents 
simultaneously, which should suggest caution when inter-
preting responses to individual treatments. The authors 
conclude that MOG antibodies should be considered in all 
childhood-onset demyelination and in adults with an atypical 
phenotype for MS, particularly if isolated or recurrent ON.
Ramanathan et  al. J Neurol Neurosurg Psychiatry. 
2018;89(2):127–137
Disease course and treatment 
responses in children with relapsing 
myelin oligodendrocyte glycoprotein 
antibody‑associated disease
This study focused on a MOG-Ab positive paediatric popu-
lation with relapsing disease. The aims of the study were 
to describe the first attack features, paraclinical character-
istics, disease course and responses to different treatment 
strategies.
In this retrospective European multicentre study, demo-
graphic, clinical and radiologic data were collected from 
patients < 18 years old with a relapsing demyelinating syn-
drome and MOG-Ab seropositivity. One hundred and two 
patients were identified with a median age of 7 years (M:F 
1.0:1.8) with the majority of patients being of Caucasian 
ethnicity. A total of 464 demyelinating events were reported 
in the cohort over a median length of follow-up of 5 years.
The most frequent demyelinating phenotype at onset was 
ADEM (52%) followed by ON (40.2%; BON 43.9%, UON 
36.6%). Simultaneous ON and TM was observed in 19.5% of 
patients. Patients 9 years or younger were more likely to have 
clinical and radiological changes affecting the brain, whereas 
events in patients older than 9 years were more likely to 
affect the optic nerve and/or TM. A CSF lymphocytosis was 
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observed in 58.7 and 11.1% had positive OCBs. Erythrocyte 
sedimentation rate was increased in 58.3% patients.
Immunomodulatory or immunosuppressive treatment was 
administered to 51% of patients. Patients received either one 
treatment (53.8%), two treatments (30.7%) or three or more 
treatments (13.5%). Although patients relapsed during all 
treatments, regular IVIg, rituximab, mycophenolate mofetil 
and azathioprine were all associated with a reduction in 
ARR. Reduction in the EDSS score was also observed in 
those patients receiving IVIg. Patients receiving immuno-
therapy had more relapses and worse EDSS than untreated 
patients (median 1.5 vs. 1.0 and 3.0 vs. 1.0) respectively. 
A good recovery, defined as an ARR and EDSS of 0 at last 
follow-up was reported in 31.3% patients.
Comment The phenotype and treatment outcomes in 
paediatric patients with MOG-Ab associated disease were 
further characterised in this paper. Interestingly, an age-
dependent phenotype was observed, which the authors sug-
gest may be related to the normal physiologic processes of 
white matter maturation. Although treated patients in this 
study had a worse outcome, this likely reflects a treatment 
paradox whereby patients with more severe initial disease 
are likely to be considered candidates for intervention. 
Although the number of patients in each treatment group 
was relatively small, the finding that IVIg was superior to 
other treatments and that injectable MS drugs were not asso-
ciated with improvement is clinically important.
Hacohen et al. JAMA Neurol. 2018;75(4):478–487
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